A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This trial is conducted in China. The aim of the trial is to investigate the influence of IBI362 on pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of warfarin, metformin, warfarin, atorvastatin, digoxin in overweight or obese subjects.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04782024` - A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults	Phase 2
	Recruiting	`NCT02745886` - Metformin Induces a Dietary Restriction-like State in Human	Phase 4

NCT number	NCT05815680
Study type	Interventional
Source	Innovent Biologics (Suzhou) Co. Ltd.
Contact
Status	Completed
Phase	Phase 1
Start date	April 6, 2023
Completion date	October 30, 2023

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms